SecBot SecBot

ARCT

Arcturus Therapeutics Holdings Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001768224 Biotech & Drug Discovery
$9.91 +0.07 (+0.71%)
Oct 26 4:00 PM ET · prev $9.84
Market cap
$305.0M
Small cap
Consensus
Buy
84% Buy or better · 19 analysts
Median target
$20.00
+102% · range $9.00–41.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.68
1 year
−6.4%
from $10.59 · Oct 27
30 days
−31.5%
from $14.46
52-week range
$5.53–16.93
−41% from high · low Jul 24
Avg volume 20D
626.4K
shares / day
Short interest
5.38M
≈18.9% of shares · −1.6%
Days to cover
5.9
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Federated Hermes, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 1,678,069 shares of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 19 added (0 new), 9 trimmed or exited.

  • AnalystsBULLISH

    16 of 19 rate it Buy or better. Median target $20.00 (+102%).

  • EstimatesRISING

    Current-quarter EPS estimate −$0.878 → −$0.680 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.6% to 5.38M shares. 5.9 days to cover, ≈18.9% of shares.

  • TrendDOWNTREND

    26% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JACOBS LEVY EQUITY MANAGEMENT, INCDOUBLED647,511$4.4M
D. E. Shaw & Co., Inc.ADD392,358$2.6M
MILLENNIUM MANAGEMENT LLCTRIM336,996$2.3M
GOLDMAN SACHS GROUP INCADD309,863$2.1M
BNP PARIBAS FINANCIAL MARKETSADD261,789$1.8M
Point72 Asset Management, L.P.DOUBLED231,582$1.6M
Jump Financial, LLCDOUBLED138,209$928.8K
Russell Investments Group, Ltd.DOUBLED75,903$510.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 84% rate it Buy or better
Strong Buy6Buy10Hold3Sell0Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies +102%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 9, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 24, 2026Citigroup
UPGRADE
UPGRADEBuy
Sep 24, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 2, 2026Freedom Broker
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 5, 2026
Marquet Magda
Director
AWARD15,000 sh
Jun 5, 2026
Marantz Jing L.
Director
AWARD15,000 sh
Jun 5, 2026
Slaoui Moncef
Director
AWARD15,000 sh
Jun 5, 2026
Markels John
Director
AWARD15,000 sh
Jun 5, 2026
BARLOW JAMES F
Director
AWARD15,000 sh
Jun 5, 2026
FARRELL PETER C
Director
AWARD15,000 sh
Jun 5, 2026
HOLMES EDWARD W
Director
AWARD15,000 sh
May 1, 2026
MULROY DENNIS
Chief Financial Officer
AWARD100,000 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.68
EPS estimate, this quarter
+23%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.68-$0.92–-$0.29-1.5%$8.0M
Next Q-$0.93-$1.55–-$0.52-2.9%$5.7M
Current FY-$3.45-$4.58–-$2.95-1.1%$18.6M
Next FY-$3.70-$4.89–-$1.99-2.5%$28.8M

Short side

FINRA· Sep 30, 2026
5,378,106
shares short
-1.6%
vs prior settlement
5.9
days to cover
≈18.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 7, 2026 SEC
Federated Hermes, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 1,678,069 shares of Arcturus…
SC 13G/A — Impact 3/10
Sep 28, 2026 SEC
A federal district court issued a case management order in Arcturus's trade secret litigation against AbbVie/Capstan…
COURT-RULING — Impact 2/10
Sep 28, 2026 Event
Arcturus Therapeutics, Inc. v. AbbVie Inc. et al
Court ruling (casd) — Docket: 3:25-cv-02494
Aug 25, 2026 SEC
Arcturus Therapeutics presented a poster on its ARCT-810 mRNA therapy for Ornithine Transcarbamylase (OTC) Deficiency…
8-K — Impact 3/10
Aug 6, 2026 Earnings calendar
ARCT Q2 2026 Earnings Scheduled — 2026-08-06
Jun 30, 2026 Inst.
JACOBS LEVY EQUITY MANAGEMENT, — DOUBLED
647,511 shares ($4.4M)
Jun 30, 2026 Inst.
D. E. Shaw & — ADD
392,358 shares ($2.6M)
Jun 5, 2026 Insider
Marquet Magda was granted 15,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
ARCT Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Sep 28, 2026
Enforcement
Arcturus Therapeutics, Inc. v. AbbVie Inc. et al
Court ruling (casd) — Docket: 3:25-cv-02494
Sep 4, 2026
Clinical Trial
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
Phase 2 · COMPLETED
Aug 6, 2026
Earnings date
ARCT Q2 2026 Earnings Scheduled — 2026-08-06
May 7, 2026
Earnings date
ARCT Q1 2026 Earnings Scheduled — 2026-05-07
Mar 3, 2026
Earnings date
ARCT Q4 2025 Earnings After Market Close — 2026-03-03

SecBot reports

5 filings · 2 bullish · 0 bearish · 3 neutral
All ARCT filing & press-release reports (5)